Brain & spine · 2024
Assessment of the efficacy and safety of neuroendoscopic procedures for intracranial pathologies: A single-centre retrospective study with 318 intracranial endoscopic procedures.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Issa Mohammed, Dannehl Clara, Büsken Carmen J, Ueding Nieke, Seitz Angelika, Krieg Sandro M, Unterberg Andreas W, El Damaty Ahmed
Аннотация
INTRODUCTION: Neuroendoscopy has become a well-established procedure for treating various intracranial conditions.
RESEARCH QUESTION: We evaluated the advantages of that technique, with focus on adverse events.
MATERIAL AND METHODS: Retrospective analysis included all patients who underwent neuroendoscopic procedures between January 2017 and December 2023. We conducted comparative analysis considering factors such as age, gender, follow-up duration, etiology, preoperative symptoms, clinical and radiological benefits, as well as surgical and nonsurgical adverse events rates.
RESULTS: Total of 318 neuroendoscopic procedures within 257 surgeries in 225 patients were included, with mean age of 18.8 ± 21.4 years. 170 cases (66.1%) were pediatric versus 87 cases adults (33.9%). Most common aetiologies were peri- and intraventricular cysts (27.2%), idiopathic aqueduct stenosis (24.9%), tumours (23.7%), and post-haemorrhagic hydrocephalus (17.1%). Procedures included endoscopic third ventriculostomy (51.0%), cyst fenestration (21.0%), and endoscopic-assisted ventricular catheter placements (19.5%). Headache was predominant preoperative symptom (42.0%). During follow-up, 84.8% and 82.5% of cases showed clinical and radiological improvement, respectively. Early surgical adverse events were observed in 5.4% of cases, while non-surgical adverse events occurred in 3.1%. There was no significant difference in the surgical adverse events rate between children and adults (4.7% vs. 6.9%, p = 0.563), compared to significant higher non-surgical adverse events in adults (6.9% vs 1.2%, p=0.020).
DISCUSSION AND CONCLUSION: Neuroendoscopy has demonstrated effectiveness and safety in treating intracranial diseases, boasting a low adverse events rate. Our study found no significant difference in the surgical adverse events rates between pediatric and adult groups.
RESEARCH QUESTION: We evaluated the advantages of that technique, with focus on adverse events.
MATERIAL AND METHODS: Retrospective analysis included all patients who underwent neuroendoscopic procedures between January 2017 and December 2023. We conducted comparative analysis considering factors such as age, gender, follow-up duration, etiology, preoperative symptoms, clinical and radiological benefits, as well as surgical and nonsurgical adverse events rates.
RESULTS: Total of 318 neuroendoscopic procedures within 257 surgeries in 225 patients were included, with mean age of 18.8 ± 21.4 years. 170 cases (66.1%) were pediatric versus 87 cases adults (33.9%). Most common aetiologies were peri- and intraventricular cysts (27.2%), idiopathic aqueduct stenosis (24.9%), tumours (23.7%), and post-haemorrhagic hydrocephalus (17.1%). Procedures included endoscopic third ventriculostomy (51.0%), cyst fenestration (21.0%), and endoscopic-assisted ventricular catheter placements (19.5%). Headache was predominant preoperative symptom (42.0%). During follow-up, 84.8% and 82.5% of cases showed clinical and radiological improvement, respectively. Early surgical adverse events were observed in 5.4% of cases, while non-surgical adverse events occurred in 3.1%. There was no significant difference in the surgical adverse events rate between children and adults (4.7% vs. 6.9%, p = 0.563), compared to significant higher non-surgical adverse events in adults (6.9% vs 1.2%, p=0.020).
DISCUSSION AND CONCLUSION: Neuroendoscopy has demonstrated effectiveness and safety in treating intracranial diseases, boasting a low adverse events rate. Our study found no significant difference in the surgical adverse events rates between pediatric and adult groups.